The DOI matches its Crossref record; 82 of the 82 references it cites were found in a registry or an index.
Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma
Open accessAbstract
The immunotherapeutic agent ipilimumab has helped address a significant unmet need in the treatment of advanced melanoma. Ipilimumab is a fully human monoclonal antibody that targets cytotoxic T‐lymphocyte antigen‐4 (CTLA‐4), thereby augmenting antitumor immune responses. After decades in which a number of clinical trials were conducted, ipilimumab was the first therapy to improve overall survival in a randomized, controlled phase III trial of patients with advanced melanoma. These results led to the regulatory approval of ipilimumab at 3 mg/kg for the treatment of unresectable or metastatic melanoma. More than 17,000 patients worldwide have received ipilimumab, either as a commercial drug at 3 mg/kg or in clinical trials and expanded access programs at different doses. Consistent with its proposed mechanism of action, the most common toxicities associated with ipilimumab therapy are inflammatory in nature. These immune‐related adverse events were mostly reversible when effective treatment guidelines were followed. Importantly, long‐term follow‐up of patients who received ipilimumab in a phase III trial showed that 24% survived at least two years, and in phase II studies, a proportion of patients survived at least five years. Evaluation of ipilimumab is ongoing in the adjuvant setting for melanoma, and for advanced disease in nonsmall cell lung, small cell lung, prostate, ovarian, and gastric cancers.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Self-citationSafety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Self-citationJemal, A., Siegel, R., Xu, J., & Ward, E. (2010) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20073 · Cited by 12,596
Reporting results of cancer treatment
Miller, A. B., Hoogstraten, B., Staquet, M., & Winkler, A. (1981) · Cancer · doi:10.1002/1097-0142(19810101)47:1<207::aid-cncr2820470134>3.0.co;2-6 · Cited by 7,793
Improved survival with vemurafenib in melanoma with BRAF V600E mutation
Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103782 · Cited by 7,720
Self-citationIpilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
Robert, C., Thomas, L., Bondarenko, I., O'Day, S., Weber, J., Garbe, C., Lebbe, C., Baurain, J.-F., Testori, A., Grob, J.-J., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1104621 · Cited by 4,496
Self-citationTrastuzumab-Induced Hepatotoxicity: A Case Report
Vucicevic, D., Carey, E. J., & Karlin, N. J. (2013) · Breast Care · doi:10.1159/000346844 · Cited by 4,415
Brocken, P., van der Heijden, H. F. M., Dekhuijzen, P. N. R., Peters-Bax, L., & de Geus-Oei, L.-F. (2014) · Respiration · doi:10.1159/000347096 · Cited by 4,002
Enhancement of Antitumor Immunity by CTLA-4 Blockade
Leach, D. R., Krummel, M. F., & Allison, J. P. (1996) · Science · doi:10.1126/science.271.5256.1734 · Cited by 3,955
Self-citationWolchok, J. D., Hoos, A., O'Day, S., Weber, J. S., Hamid, O., Lebbé, C., Maio, M., Binder, M., Bohnsack, O., Nichol, G., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1624 · Cited by 3,222
Self-citationTivol, E. A., Borriello, F., Schweitzer, A. N., Lynch, W. P., Bluestone, J. A., & Sharpe, A. H. (1995) · Immunity · doi:10.1016/1074-7613(95)90125-6 · Cited by 2,914
Lymphoproliferative Disorders with Early Lethality in Mice Deficient in Ctla-4
Waterhouse, P., Penninger, J. M., Timms, E., Wakeham, A., Shahinian, A., Lee, K. P., Thompson, C. B., Griesser, H., & Mak, T. W. (1995) · Science · doi:10.1126/science.270.5238.985 · Cited by 2,766
Paradoxical roles of the immune system during cancer development
de Visser, K. E., Eichten, A., & Coussens, L. M. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1782 · Cited by 2,256
CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation.
Krummel, M. F., & Allison, J. P. (1995) · The Journal of experimental medicine · doi:10.1084/jem.182.2.459 · Cited by 2,245
Self-citationImmunologic Correlates of the Abscopal Effect in a Patient with Melanoma
Postow, M. A., Callahan, M. K., Barker, C. A., Yamada, Y., Yuan, J., Kitano, S., Mu, Z., Rasalan, T., Adamow, M., Ritter, E., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1112824 · Cited by 2,087
Self-citationBlackburn, S. D., Shin, H., Haining, W. N., Zou, T., Workman, C. J., Polley, A., Betts, M. R., Freeman, G. J., Vignali, D. A. A., & Wherry, E. J. (2009) · Nature Immunology · doi:10.1038/ni.1679 · Cited by 2,062
Caligiuri, M. A. (2008) · Blood · doi:10.1182/blood-2007-09-077438 · Cited by 1,905
The Concept of Immunological Surveillance
Burnet, F. M. (2015) · Progress in Tumor Research · doi:10.1159/000386035 · Cited by 1,656
Management of Immune-Related Adverse Events and Kinetics of Response With Ipilimumab
Weber, J. S., Kähler, K. C., & Hauschild, A. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.41.6750 · Cited by 1,415
Self-citationWolchok, J. D., Neyns, B., Linette, G., Negrier, S., Lutzky, J., Thomas, L., Waterfield, W., Schadendorf, D., Smylie, M., Guthrie, T., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70334-1 · Cited by 1,195
Self-citationIpilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial
Margolin, K., Ernstoff, M. S., Hamid, O., Lawrence, D., McDermott, D., Puzanov, I., Wolchok, J. D., Clark, J. I., Sznol, M., Logan, T. F., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70090-6 · Cited by 1,091
Self-citationvan Elsas, A., Hurwitz, A. A., & Allison, J. P. (1999) · The Journal of Experimental Medicine · doi:10.1084/jem.190.3.355 · Cited by 1,020
Self-citationAttia, P., Phan, G. Q., Maker, A. V., Robinson, M. R., Quezado, M. M., Yang, J. C., Sherry, R. M., Topalian, S. L., Kammula, U. S., Royal, R. E., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.06.205 · Cited by 1,012
Lynch, T. J., Bondarenko, I., Luft, A., Serwatowski, P., Barlesi, F., Chacko, R., Sebastian, M., Neal, J., Lu, H., Cuillerot, J.-M., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.38.4032 · Cited by 1,002
Krummel, M. F., & Allison, J. P. (1996) · The Journal of experimental medicine · doi:10.1084/jem.183.6.2533 · Cited by 932
Self-citationRibas, A., Kefford, R., Marshall, M. A., Punt, C. J. A., Haanen, J. B., Marmol, M., Garbe, C., Gogas, H., Schachter, J., Linette, G., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.44.6112 · Cited by 805
Finn, O. J. (2008) · New England Journal of Medicine · doi:10.1056/nejmra072739 · Cited by 774
The toxins of William B. Coley and the treatment of bone and soft-tissue sarcomas.
McCarthy, E. F. (2006) · Europe PMC (PubMed Central) · Cited by 747
Korn, E. L., Liu, P.-Y., Lee, S. J., Chapman, J.-A. W., Niedzwiecki, D., Suman, V. J., Moon, J., Sondak, V. K., Atkins, M. B., Eisenhauer, E. A., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.7837 · Cited by 705
Novel cancer immunotherapy agents with survival benefit: recent successes and next steps
Sharma, P., Wagner, K., Wolchok, J. D., & Allison, J. P. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3153 · Cited by 642
Self-citationImmunotherapy: past, present and future
Waldmann, T. A. (2003) · Nature Medicine · doi:10.1038/nm0303-269 · Cited by 628
Immunostimulatory monoclonal antibodies for cancer therapy
Melero, I., Hervas-Stubbs, S., Glennie, M., Pardoll, D. M., & Chen, L. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2051 · Cited by 627
Reck, M., Bondarenko, I., Luft, A., Serwatowski, P., Barlesi, F., Chacko, R., Sebastian, M., Lu, H., Cuillerot, J.-M., & Lynch, T. J. (2013) · Annals of Oncology · doi:10.1093/annonc/mds213 · Cited by 611
Immuno-oncology: understanding the function and dysfunction of the immune system in cancer
Finn, O. J. (2012) · Annals of Oncology · doi:10.1093/annonc/mds256 · Cited by 594
Systematic Review of Medical Treatment in Melanoma: Current Status and Future Prospects
Garbe, C., Eigentler, T. K., Keilholz, U., Hauschild, A., & Kirkwood, J. M. (2011) · The Oncologist · doi:10.1634/theoncologist.2010-0190 · Cited by 582
Checkpoint Blockade in Cancer Immunotherapy
Korman, A. J., Peggs, K. S., & Allison, J. P. (2006) · Advances in Immunology · doi:10.1016/s0065-2776(06)90008-x · Cited by 570
Self-citationWeber, J., Thompson, J. A., Hamid, O., Minor, D., Amin, A., Ron, I., Ridolfi, R., Assi, H., Maraveyas, A., Berman, D., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1024 · Cited by 568
Self-citationSlovin, S. F., Higano, C. S., Hamid, O., Tejwani, S., Harzstark, A., Alumkal, J. J., Scher, H. I., Chin, K., Gagnier, P., McHenry, M. B., et al. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt107 · Cited by 559
Hamid, O., Schmidt, H., Nissan, A., Ridolfi, L., Aamdal, S., Hansson, J., Guida, M., Hyams, D. M., Gómez, H., Bastholt, L., et al. (2011) · Journal of Translational Medicine · doi:10.1186/1479-5876-9-204 · Cited by 534
Self-citationImproved Endpoints for Cancer Immunotherapy Trials
Hoos, A., Eggermont, A. M. M., Janetzki, S., Hodi, F. S., Ibrahim, R., Anderson, A., Humphrey, R., Blumenstein, B., Old, L., & Wolchok, J. (2010) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djq310 · Cited by 518
Self-citationO'Day, S. J., Maio, M., Chiarion-Sileni, V., Gajewski, T. F., Pehamberger, H., Bondarenko, I. N., Queirolo, P., Lundgren, L., Mikhailov, S., Roman, L., et al. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq013 · Cited by 514
Self-citationMaker, A. V., Phan, G. Q., Attia, P., Yang, J. C., Sherry, R. M., Topalian, S. L., Kammula, U. S., Royal, R. E., Haworth, L. R., Levy, C., et al. (2005) · Annals of Surgical Oncology · doi:10.1245/aso.2005.03.536 · Cited by 492
CTLA-4 Blockade with Ipilimumab: Long-term Follow-up of 177 Patients with Metastatic Melanoma
Prieto, P. A., Yang, J. C., Sherry, R. M., Hughes, M. S., Kammula, U. S., White, D. E., Levy, C. L., Rosenberg, S. A., & Phan, G. Q. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1823 · Cited by 477
Principles and use of anti-CTLA4 antibody in human cancer immunotherapy
Peggs, K. S., Quezada, S. A., Korman, A. J., & Allison, J. P. (2006) · Current Opinion in Immunology · doi:10.1016/j.coi.2006.01.011 · Cited by 445
Self-citationRe-evaluating the role of dacarbazine in metastatic melanoma: what have we learned in 30 years?
Eggermont, A. M. M., & Kirkwood, J. M. (2004) · European Journal of Cancer · doi:10.1016/j.ejca.2004.04.030 · Cited by 383
Two Hundred Years of Cancer Research
DeVita, V. T., & Rosenberg, S. A. (2012) · New England Journal of Medicine · doi:10.1056/nejmra1204479 · Cited by 318
Hersh, E. M., O’Day, S. J., Powderly, J., Khan, K. D., Pavlick, A. C., Cranmer, L. D., Samlowski, W. E., Nichol, G. M., Yellin, M. J., & Weber, J. S. (2011) · Investigational New Drugs · doi:10.1007/s10637-009-9376-8 · Cited by 307
Self-citationDi Giacomo, A. M., Ascierto, P. A., Pilla, L., Santinami, M., Ferrucci, P. F., Giannarelli, D., Marasco, A., Rivoltini, L., Simeone, E., Nicoletti, S. V., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70324-8 · Cited by 284
Raising the Bar: The Curative Potential of Human Cancer Immunotherapy
Rosenberg, S. A. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003634 · Cited by 244
Development of Ipilimumab: Contribution to a New Paradigm for Cancer Immunotherapy
Hoos, A., Ibrahim, R., Korman, A., Abdallah, K., Berman, D., Shahabi, V., Chin, K., Canetta, R., & Humphrey, R. (2010) · Seminars in Oncology · doi:10.1053/j.seminoncol.2010.09.015 · Cited by 242
Self-citationTumor immunoediting and immunosculpting pathways to cancer progression
Reiman, J. M., Kmieciak, M., Manjili, M. H., & Knutson, K. L. (2007) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2007.06.009 · Cited by 199
New drugs in melanoma: It’s a whole new world
Eggermont, A. M. M., & Robert, C. (2011) · European Journal of Cancer · doi:10.1016/j.ejca.2011.06.052 · Cited by 186
Self-citationThe Yin and Yang of T Cell Costimulation
Allison, J. P., & Krummel, M. F. (1995) · Science · doi:10.1126/science.270.5238.932 · Cited by 180
Self-citationWolchok, J. D., Weber, J. S., Maio, M., Neyns, B., Harmankaya, K., Chin, K., Cykowski, L., de Pril, V., Humphrey, R., & Lebbé, C. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt161 · Cited by 176
Self-citationKaehler, K. C., Piel, S., Livingstone, E., Schilling, B., Hauschild, A., & Schadendorf, D. (2010) · Seminars in Oncology · doi:10.1053/j.seminoncol.2010.09.003 · Cited by 170
Cancer Prevention: From 1727 to Milestones of the Past 100 Years
Lippman, S. M., & Hawk, E. T. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-1750 · Cited by 165
Diagnosis and Treatment of mela-noma Brain Metastasis: A Literature Review
Sloan, A. E., Nock, C. J., & Einstein, D. B. (2009) · Cancer Control · doi:10.1177/107327480901600307 · Cited by 161
MOKYR, M. B., Kalinichenko, T. V., Gorelik, L., & Bluestone, J. A. (1998) · PubMed · Cited by 147
Activity and Safety of CTLA-4 Blockade Combined with Vaccines in Cynomolgus Macaques
Keler, T., Halk, E., Vitale, L. A., O’Neill, T., Blanset, D. L., Lee, S., Srinivasan, M., Graziano, R. F., Davis, T. A., Lönberg, N., et al. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.171.11.6251 · Cited by 142
Self-citationWeber, J. S., Hamid, O., Chasalow, S. D., Wu, D., Parker, S. M., Galbraith, S. M., Gnjatic, S., & Berman, D. (2011) · Journal of Immunotherapy · doi:10.1097/cji.0b013e31823aa41c · Cited by 124
Self-citationCTLA-4 blockade: therapeutic potential in cancer treatments
Tarhini, A. A., & Iqbal, F. (2010) · OncoTargets and Therapy · doi:10.2147/ott.s4833 · Cited by 97
Do We Need a Different Set of Response Assessment Criteria for Tumor Immunotherapy?
Ribas, A., Chmielowski, B., & Glaspy, J. A. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-2376 · Cited by 95
Pennock, G. K., Waterfield, W. C., & Wolchok, J. D. (2011) · American Journal of Clinical Oncology · doi:10.1097/coc.0b013e318209cda9 · Cited by 90
Self-citationRadiotherapy augments the immune response to prostate cancer in a time‐dependent manner
Harris, T. J., Hipkiss, E. L., Borzillary, S., Wada, S., Grosso, J. F., Yen, H., Getnet, D., Bruno, T. C., Goldberg, M. V., Pardoll, D. M., et al. (2008) · The Prostate · doi:10.1002/pros.20794 · Cited by 89
Shahabi, V., Whitney, G. S., Hamid, O., Schmidt, H., Chasalow, S. D., Alaparthy, S., & Jackson, J. R. (2012) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-012-1227-3 · Cited by 84
Tremelimumab: A Review of Development to Date in Solid Tumors
Tarhini, A. A. (2013) · Immunotherapy · doi:10.2217/imt.13.9 · Cited by 76
The confluence of radiotherapy and immunotherapy
Burnette, B., Fu, Y., & Weichselbaum, R. R. (2012) · Frontiers in Oncology · doi:10.3389/fonc.2012.00143 · Cited by 67
A methodological framework to enhance the clinical success of cancer immunotherapy
Hoos, A., Britten, C. M., Huber, C., & O’Donnell-Tormey, J. (2011) · Nature Biotechnology · doi:10.1038/nbt.2000 · Cited by 60
Self-citationAdvances in systemic treatment of melanoma
Eggermont, A. M. M. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq364 · Cited by 57
Agarwala, S. S. (2010) · Melanoma Research · doi:10.1097/cmr.0b013e328333bbc8 · Cited by 42
Hepatic failure in a patient treated with dacarbazine (DTIC) for malignant melanoma
Frosch, P. J., Czarnetzki, B. M., Macher, E., Grundmann, E., & Gottschalk, I. (1979) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/bf00410649 · Cited by 36
Weide, B., Martens, A., Wistuba‐Hamprecht, K., Zelba, H., Maier, L., Lipp, H., Klumpp, B. D., Soffel, D., Eigentler, T., & Garbe, C. (2016) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-016-1944-0 · Cited by 35
Current status of immunotherapy for the treatment of lung cancer.
Murala, S., Alli, V. V., Kreisel, D., Gelman, A. E., & Krupnick, A. S. (2010) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2072-1439.2010.11.6 · Cited by 25
Dacarbazine (DTIC)-induced human liver damage light and electron-microscopic findings.
Dancygier, H., Runne, U., Leuschner, U., Milbradt, R., & Claßen, M. (1983) · PubMed · Cited by 22
Lebbé, C., Weber, J. S., Maio, M., Neyns, B., Harmankaya, K., Chin, K. M., McDowell, D. O., Cykowski, L., McHenry, M. B., & Wolchok, J. D. (2012) · Annals of Oncology · doi:10.1016/s0923-7534(20)33712-1 · Cited by 20
Self-citationAgarwala, S. S., & O'Day, S. J. (2010) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2010.06.001 · Cited by 18
Self-citationShaw, H. M., & Nathan, P. (2013) · Expert Review of Anticancer Therapy · doi:10.1586/era.13.24 · Cited by 18
Regulation of Tumor Progression by Anti-Neoplastic T Cell Responses
Abrams, S. I. (2004) · Cancer Biology & Therapy · doi:10.4161/cbt.3.2.758 · Cited by 9
Cited by
Schadendorf, D., Hodi, F. S., Robert, C., Weber, J. S., Margolin, K., Hamid, O., Patt, D., Chen, T.-T., Berman, D. M., & Wolchok, J. D. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.56.2736 · Cited by 2,141
Self-citationTherapeutic developments in pancreatic cancer: current and future perspectives
Neoptolemos, J. P., Kleeff, J., Michl, P., Costello, E., Greenhalf, W., & Palmer, D. H. (2018) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-018-0005-x · Cited by 1,170
TGFβ biology in cancer progression and immunotherapy
Derynck, R., Turley, S. J., & Akhurst, R. J. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0403-1 · Cited by 944
Nishino, M., Giobbie-Hurder, A., Hatabu, H., Ramaiya, N. H., & Hodi, F. S. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2016.2453 · Cited by 758
Self-citationNext generation antibody drugs: pursuit of the 'high-hanging fruit'
Carter, P. J., & Lazar, G. A. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.227 · Cited by 754
Metadata
- Authors
- Wolchok, J. D., Hodi, F. S., Weber, J. S., Allison, J. P., Urba, W. J., Robert, C., O'Day, S. J., Hoos, A., Humphrey, R., Berman, D. M., Lonberg, N., & Korman, A. J.
- Venue
- Annals of the New York Academy of Sciences
- Publisher
- Wiley
- Published
- 2013-06-17
- Volume
- 1291
- Issue
- 1
- Pages
- 1-13
- ISSN
- 0077-8923 (ISSN-L)
- 1749-6632
- OpenAlex
- W2111877246
- Cited by
- 303
- References
- 82
- FWCI
- 18.50
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.